Pınar Özçelik

Pınar Özçelik

Auto-generated profile, based on publicly available information

Pınar Özçelik

Faculty of Medicine, Department of Neurology, Dokuz Eylul University, Izmir, Turkey

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The Lancet Neurology
Verified
Journal Article
Closed access
JHJames F Howard
James F Howard
KUKimiaki Utsugisawa
Kimiaki Utsugisawa
MBMichael Benatar
Michael Benatar
HMHiroyuki Murai
Hiroyuki Murai
RBRichard J Barohn
Richard J Barohn
HVHong Vu
Hong Vu

8 March 2022 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
NÇNeşe Çelebisoy
Neşe Çelebisoy
AAAyşın Kısabay Ak
Ayşın Kısabay Ak
HÖHüseyin Nezih Özdemir
Hüseyin Nezih Özdemir
FGFigen Gökçay
Figen Gökçay
GDGülsüm Saruhan Durmaz
Gülsüm Saruhan Durmaz
FUFeray Güleç Uyaroğlu
Feray Güleç Uyaroğlu

9 June 2021 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
PÖPınar Özçelik
Pınar Özçelik
KKKoray Koçoğlu
Koray Koçoğlu
VÖVesile Öztürk
Vesile Öztürk
PKPembe Keskinoğlu
Pembe Keskinoğlu
GAGülden Akdal
Gülden Akdal

1 June 2017 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
PDF file
SOSerkan Ozakbas
Serkan Ozakbas
BCBilge Piri Cinar
Bilge Piri Cinar
PÖPinar Özcelik
Pinar Özcelik
HBHatice Baser
Hatice Baser
GKGorkem Kosehasanoğullari
Gorkem Kosehasanoğullari

24 October 2019 in International Journal of Neuroscience
Verified
Journal Article
Closed access
ZKZerrin Karaaslan
Zerrin Karaaslan
PÖPınar Özçelik
Pınar Özçelik
ÇUÇağrı Ulukan
Çağrı Ulukan
CUCanan Ulusoy
Canan Ulusoy
KOKadir Serkan Orhan
Kadir Serkan Orhan
GAGülden Akdal
Gülden Akdal
Objectives: Vestibular migraine (VM) is an under-recognized entity with substantial burden for the individual and society. The underlying mechanism of VM and its distinction from other migraine mechanisms still remain unclear. Inflammatory pathways have been suggested to contribute to vestibular migraine. Our aim was to further investigate the possible role of inflammation in the pathophysiology of VM. Methods: We recruited 30 patients with VM diagnosed according to ICHD-3 criteria and 26 gender- and age-matched healthy controls. Blood samples were obtained from 11 VM patients during an attack and from 13 VM patients under prophylactic treatment. Plasma levels of calcitonin gene related peptide (CGRP), neurokinin A (NKA), substance P (SP), NLRP1, NLRP3, caspase-1, IL-1β, IL-6, TNF-α and NFκB were measured by ELISA. Results: IL-6 levels were significantly reduced in VM patients, whereas levels of other inflammation parameters were comparable to those of healthy controls. Levels of inflammatory mediators were not correlated with clinical parameters. Likewise, there were no significant differences among VM patients with and without headache attack and prophylactic treatment. Conclusion: Our results argue against involvement of systemic inflammation in the pathophysiology of VM.

1 December 2019 in Journal of the Neurological Sciences
Verified
Journal Article
Open access
HMHiroyuki Murai
Hiroyuki Murai
AUAkiyuki Uzawa
Akiyuki Uzawa
YSYasushi Suzuki
Yasushi Suzuki
TITomihiro Imai
Tomihiro Imai
HSHirokazu Shiraishi
Hirokazu Shiraishi
HVHong Vu
Hong Vu
The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229). In this 52-week sub-analysis of the open-label extension of REGAIN (NCT02301624), eculizumab's efficacy and safety were assessed in 11 Japanese and 88 Caucasian patients with anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis. For patients who had received placebo during REGAIN, treatment with open-label eculizumab resulted in generally similar outcomes in the Japanese and Caucasian populations. Rapid improvements were maintained for 52 weeks, assessed by change in score from open-label extension baseline to week 52 (mean [standard error]) using the following scales (in Japanese and Caucasian patients, respectively): Myasthenia Gravis Activities of Daily Living (-2.4 [1.34] and - 3.3 [0.65]); Quantitative Myasthenia Gravis (-2.9 [1.98] and - 4.3 [0.79]); Myasthenia Gravis Composite (-4.5 [2.63] and - 4.9 [1.19]); and Myasthenia Gravis Quality of Life 15-item questionnaire (-8.6 [5.68] and - 6.5 [1.93]). Overall, the safety of eculizumab was consistent with its known safety profile. In this interim sub-analysis, the efficacy and safety of eculizumab in Japanese and Caucasian patients were generally similar, and consistent with the overall REGAIN population.